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Investigations into the activity of roxithromycin against murine toxoplasma
infections are reviewed. Roxithromycin is an active drug against murine
toxoplasmosis after intraperitoneal challenge with the RH strain of Toxoplasma
gondii. Roxithromycin protected 100% of mice after five daily doses of 540 mg per
kg administered by gavage. The cure rate after treatment of peritoneal infections
seemed to be related to the length of the therapy. Roxithromycin also decreased the
number of toxoplasma cysts, after intracerebral infection with the C56 strain and
showed synergistic activity when combined with gamma interferon. Thus,
roxithromycin could be a worthwhile alternative to current therapy against
toxoplasma infections. Clinical studies on its activity and safety, especially in
pregnancy, are warranted.
Introduction
Infections caused by Toxoplasma gondii are very common all over the world, but only
a small percentage of those infections produce severe symptoms and significant illness.
Infections in the immunocompromised host and in pregnant women are of special
significance because they can lead to the development of very severe toxoplasmosis.
The immunocompromised host, especially with AIDS, can develop severe toxoplasma
encephalitis and up to 12% of AIDS patients who have antibodies to T. gondii do
indeed develop the disease (Hofflin, Conley & Remington, 1987). The infected fetus
often develops serious sensorial and neurological disorders. In France, there is an
estimated 6-3% risk of infection during pregnancy, and an estimated 33% incidence of
fetal infection in those women who become infected during their pregnancies
(Desmonts & Couvreur, 1974).
The most effective treatment for both acquired and congenital toxoplasmosis is the
combination of pyrimethamine and sulphadiazine (or triple sulphonamides) (Eyles &
Coleman, 1955). However, the mortality rate among immunodeficient patients with
toxoplasma encephalitis treated with this combination approaches 70% (Levy,
Bredesen & Rosemblum, 1985), and the toxicity of the combination precludes its use
during pregnancy (Kutscher, Lane & Segael, 1954; Kaufman & Geisler, 1960).
Therefore, there is a need for alternative therapy for this disease.
Spiramycin, a macrolide antibiotic, is less toxic than pyrimethamine and
sulphadiazine, but the lack of well controlled trials leaves uncertainties about its
clinical effectiveness. Spiramycin is active against murine acute toxoplasmosis (Garin
& Eyles, 1958) and has been used effectively for treating pregnant women (Desmonts &
Couvreur, 1979).
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Roxithromycin is a new macrolide antibiotic with an in-vitro antimicrobial spectrum
similar to that of erythromycin (Barlam & Neu, 1984); but roxithromycin is distinct in
that it produces higher serum levels and has a longer half-life (Puri et al., 1985).
Hence, the antitoxoplasmic activity of roxithromycin has been evaluated by several
authors in murine models. The results of these investigations will be reviewed here.
Murine models of toxoplasmosis
Mice are very susceptible to T. gondii infection; although results may vary with the
parasite and the strain of mouse. Two strains of T. gondii have been selected in the
studies reviewed here: the highly virulent RH strain described by Sabin (1941) and the
relatively virulent C56 strain. Young Swiss Webster mice weighing 15-25 g were used
in all studies. The inoculum was obtained by harvesting tachyzoites from the
peritoneal fluid of mice heavily infected for this purpose. This inoculum was
standardized by appropriate dilution after microscopic examination.
Acute toxoplasmosis after intraperitoneal inoculation
Intraperitoneal inoculation of the RH strain was used in a first model (Chan & Luft,
1986; Chang & Pechere, 1987). Less than ten tachyzoites are able to kill all the mice,
and the inoculum is standardized to be lethal in seven to nine days (5000 tachyzoites in
our model). The experimental disease is characterized by the production of ascites
containing numerous tachyzoites. At autopsy, tachyzoites are also found in most
organs, including the spleen, liver and brain. For assessing the activity of a drug in this
model the protective dose is calculated. Moreover, when no parasites are seen in the
surviving animals, the organs (especially the brain of these animals), are ground in a
mortar and portions of these suspensions are injected into untreated mice not
previously exposed to toxoplasma. The donors can be considered as cured when the
recipient mice survive 30 days after injection without having toxoplasma at autopsy.
Toxoplasma encephalitis
Toxoplasmic encephalitis can be established by intraperitoneal injection of 10,000
tachyzoites of the C56 strain into mice immunocompromised with cortisone acetate or
cyclophosphamide (Luft et al., 1986). However, the same group of researchers
developed a particularly suitable model (Hofflin, Conley & Remington, 1987). Here, an
encephalitis is produced after intracerebral inoculation of 10,000 C56 tachyzoites. With
the use of a stereotactic unit, injections are delivered into the right frontal lobe of the
brain. The mice develop necrosis at the site of inoculation surrounded by areas with
cyst formation. The therapeutic activity is assessed by survival rate, time until death
and number of toxoplasma cysts in the brain.
Effect of roxithromycin
Roxithromycin in the peritoneal model
Two studies (Chan & Luft, 1986; Chang & Pechere, 1987), dealt with the activity of
roxithromycin in this acute type of toxoplasma infection (Table I). In the study of
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Chan & Luft (1986) roxithromycin was mixed in powdered mouse-feed after the
observation that the mice consumed 4 g of feed per day. In treatments starting 24 h
after challenge and given for 28 days the 50% survival dose was 625 to 660 mg/kg per
day. The 100% survival dose was not obtained.
Chang & Pechere (1987) administered roxithromycin once a day by gavage. After
five doses, starting 24 h after challenge, the 50% and 100% survival doses were 336
and 540 mg/kg per day, respectively. The cure rate, determined according to the
number of surviving mice yielding negative results after brain transfer, seemed to be
associated with the duration of the therapy: 41% and 72%, after five and 14 days of
therapy, respectively (Chang & Pechere, 1987), and 90% after 28 days of therapy
(Chan & Luft, 1986).
Roxithromycin against toxoplasma encephalitis
In immunocompromised mice infected by the peritoneal route, roxithromycin at a dose
of 10 mg per day, mechanically mixed with chow, significantly protected mice
compared with untreated controls (Table I). Even when therapy was delayed for as
long as four days results were similar (Luft el al., 1986).
In the model of toxoplasma encephalitis after intracerebral inoculation,
roxithromycin at a daily dosage of 35 or 50 mg per mouse decreased the rate of
mortality (HofHin & Remington, 1987). Moreover, the median number of cysts in the
treated mice that survived was 142 compared with 484 in the untreated that survived.
The same study showed very interestingly that gamma interferon acted synergistically
with roxithromycin. When combined, the two agents strikingly increased the survival
of the mice.
Discussion
Roxithromycin was active in treating acute infection with the virulent RH strain of
T. gondii in mice. For the first time it has been possible to report total protection with
a macrolide in such an infection (Chang & Pechere, 1987). Of particular interest was
the fact that some surviving mice seemed completely cured according to the
subinoculation studies. However, in that study, roxithromycin appeared less effective
than the combination of pyrimethamine and sulphadiazine for treating cerebral
toxoplasmosis produced after peritoneal infection of mice with RH tachyzoites.
In the two studies dealing with acute peritoneal toxoplasmosis, the 50% survival
doses were different. The mode of administration of roxithromycin probably
accounted for this difference. In the study by Chan & Luft (1986) the total dose
required to protect 50% of the animals was approximately 18 g/kg; the antibiotic was
mixed with feed. In the study by Chang & Pechere (1987) the total dose was only
1 -6 g/kg; roxithromycin was administered by gavage in fasting mice. This procedure
assured total delivery of the drug into an empty stomach during the entire treatment
period and was likely to produce higher peak blood levels. In healthy volunteers,
roxithromycin bioavailability was reduced two-fold after a meal, compared with the
fasting state (Tremblay et al., 1986). Also, higher blood peaks could possibly produce
higher intracellular concentrations.
Thus far we have no data about the penetration of roxithromycin into the brain, but
the reduced numbers of toxoplasma cysts in the encephalitis model suggest that the
Table I. Studies on the activity of roxythromycin against T. gondii in mice
Mouse
strain/weight
T. gondii Inoculum/
strain route Therapy/route of administration
Cure rate
Time of Survival among
therapy rate % survivors Reference
C56
Swiss Webster
female 18-20 g
C56
10* ip
10* ic
10* ic
10* ic
10* ic
oral, with mouse food
cortisone acetate, non-ROX-treated
cortisone acetate + ROX 10 mg/day
cyclophosphamide, non-ROX-treated
cyclophosphamide + ROX 10 mg/day
untreated controls
ROX 10 mg/day
oral, with mouse food
untreated controls
ROX 50 mg/da/
untreated controls
ROX 35 mg/day*
untreated controls
ROX 35 mg/day*
gamma interferon 5 x 10* U*
gamma interferon 5 x 10* U + ROX 35 mg/day*
untreated controls
ROX 25 mg/day*
gamma interferon 5 x 10* U°
gamma interferon 5x10* U + ROX 25 mg/day*
NM
NM
NM
NM
0
NM
0
22 days
0
22 days
0
16 days
16 days
16 days
0
16 days
16 days
16 days
0
100
0
80
0
85
11
44
10
38
0
0
0
40
0
0
0
100
ND
ND
ND
ND
0
ND
0
ND
0
ND
0
ND
ND
ND
0
ND
ND
ND
Luft et al.
(1986)
Hofflin &
Remington, (1987)
Swiss Webster
female 15-16 g
RH
Swiss Webster
female 25 ± I g
RH
2xlO3
>P
2xlO 3
2x10*
ip
5 x I 0 3
ip
5 x l 0 3
oral, with mouse food
untreated controls
ROX 10 mg/day*
untreated controls
ROX 10 mg/day»
untreated controls
ROX 10 mg/da/
untreated controls
ROX 10 mg/day*
P-S (0044 mg/day-5 mg/day)'
untreated controls
ROX 10 mg/day*
untreated controls
ROX 10mg/da/
oral, by gavage
untreated controls
ROX SD,0: 336 mg/kg/day*
ROX SD100: 540 mg/kg/day*
SPI SD30: 300 mg/kg/day*
P-S (4-4 mg/kg/day-250 mg/kg/day)*
untreated controls
ROX SD50 360 mg/kg/day*
P-S (4-4 mg/kg/day-250 mg/kg/day/
0
28 days
0
28 days
0
28 days
0
28 days
28 days
0
28 days
0
28 days
0
5 days
5 days
5 days
5 days
0
14 days
14 days
0
100
0
90
0
80
0
50
90
0
100
0
80
0
50
100
50
90
0
50
100
0
70
0
100
0
70
0
90
100
0
80
0
100
0
59
50
59
100
0
28
100
Chan&
Luft, (1986)
Chang &
Pechere (1987)
ROX, Roxythromycin; SPI, spiramycin; P-S, pyrimethamine-sulphadiazine; ip, intraperitoneal; ic, intracerebral; SD50, survival dose 50%; SDIOO, survival dose
100%.
'Treatment started 2 h before challenge; *24 h before challenge (prophylactic treatment); C48 h before challenge; '2-3 h after challenge (dose-response study); *24h
after challenge (delayed treatment).
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antibiotic exerts an effect in the brain parenchyma. These findings raise the hope that
roxithromycin may have an activity against toxoplasma encephalitis in AIDS patients.
This hope, however, must be confirmed by clinical studies.
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